Literature DB >> 1394121

Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice.

S K Huang1, K D Lee, K Hong, D S Friend, D Papahadjopoulos.   

Abstract

Using light and electron microscopy, we investigated the in vivo distribution of liposomes sterically stabilized by specific lipids which prolong their circulation in blood. Tissue distribution of sterically stabilized liposomes composed of distearoyl phosphatidylcholine:cholesterol:monosialoganglioside GM1 (10:5:1)-encapsulated 67Ga-Desferal indicates that more than 30% of liposomes still remain in the blood at 24 h after tail vein injection. Moreover, such liposomes accumulated in tumors (C-26 colon carcinoma cells implanted s.c.), reaching almost the same level of uptake as liver (approximately 20% injected dose/g tissue). The microscopic localization of liposomes labeled with encapsulated colloidal gold or rhodamine-labeled dextran coincided well with the tissue distribution. To evaluate circulation parameters, two sizes of gold-containing egg phosphatidylcholine:cholesterol:distearoyl phosphatidylethanolamine (derivatized at its amino position with a 1900 molecular weight segment of polyethylene glycol) (10:5:0.8) liposomes were injected. The plasma was examined by electron microscopy of negative-stained preparations at 0.5, 4, and 24 h after liposome injection. It was found that the ratio of small (less than 100 nm diameter) to large (greater than 100 nm) liposomes increased with time, indicating a much faster clearance of the larger liposomes. To detect the localization of liposomes in various tissues, appropriate samples were fixed 24 h after the injection of gold-containing liposomes (between 80 and 100 nm in diameter) composed of egg phosphatidylcholine:cholesterol:monosialoganglioside GM1 (10:5:1) or egg phosphatidylcholine:cholesterol:derivatized distearoyl phosphatidylethanolamine. The tissues examined for this study included normal liver, bone marrow, and implanted neoplasms. Silver-enhanced colloidal gold was found predominantly within Kupffer cells in the normal liver and within macrophages in the bone marrow. Rarely were any silver-enhanced gold particles detected in hepatocytes. In all preparations, electron microscopy revealed the presence of gold in endosomes and lysosomes of fixed sinusoidal lining macrophages in the liver and bone marrow. Peripheral to the implanted tumors, silver enhancement revealed gold in small blood vessels and focally beyond the vessel boundaries in extracellular spaces around tumor cells. Gold particles were not observed within the tumor cell cytoplasm. At the tumor border, nonenhanced gold was occasionally seen by electron microscopy in cells of the mononuclear phagocyte system. We obtained the same localization pattern as with silver enhancement by using an alternative aqueous content marker, rhodamine B isothiocyanate-dextran. We conclude that liposomes of specific composition, which have the ability to remain in circulation with a half-life of 12-24 h, are also able to transverse the endothelium of small blood vessels, including those in tumors, and extravasate into extracellular spaces.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1394121

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

1.  Supramolecular materials via polymerization of mesophases of hydrated amphiphiles.

Authors:  Anja Mueller; David F O'Brien
Journal:  Chem Rev       Date:  2002-03       Impact factor: 60.622

2.  Hemoglobin-vesicles as oxygen carriers: influence on phagocytic activity and histopathological changes in reticuloendothelial system.

Authors:  H Sakai; H Horinouchi; K Tomiyama; E Ikeda; S Takeoka; K Kobayashi; E Tsuchida
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

3.  A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells.

Authors:  A W El-Kareh; T W Secomb
Journal:  Neoplasia       Date:  2000 Jul-Aug       Impact factor: 5.715

4.  Liposome-mediated therapy of intracranial brain tumors in a rat model.

Authors:  U S Sharma; A Sharma; R I Chau; R M Straubinger
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

5.  Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model.

Authors:  Robert D Arnold; Donald E Mager; Jeanine E Slack; Robert M Straubinger
Journal:  Clin Cancer Res       Date:  2005-12-15       Impact factor: 12.531

6.  Increased liposome extravasation in selected tissues: effect of substance P.

Authors:  J Rosenecker; W Zhang; K Hong; J Lausier; P Geppetti; S Yoshihara; D Papahadjopoulos; J A Nadel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

7.  Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors.

Authors:  T Nomura; N Koreeda; F Yamashita; Y Takakura; M Hashida
Journal:  Pharm Res       Date:  1998-01       Impact factor: 4.200

Review 8.  Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.

Authors:  Alberto Gabizon; Hilary Shmeeda; Yechezkel Barenholz
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer.

Authors:  David I Rosenthal; Sue S Yom; Li Liu; Mitchell Machtay; Kenneth Algazy; Randal S Weber; Gregory S Weinstein; Ara A Chalian; Linda K Mille; Kenneth Rockwell; Margaret Tonda; Edward Schnipper; Diane Hershock
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

10.  Novel Gd nanoparticles enhance vascular contrast for high-resolution magnetic resonance imaging.

Authors:  Tot Bui; Jeff Stevenson; John Hoekman; Shanrong Zhang; Kenneth Maravilla; Rodney J Y Ho
Journal:  PLoS One       Date:  2010-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.